Pluri Inc. (NASDAQ:PLUR)
| Market Cap | 11.01M-75.0% |
| Revenue (ttm) | 1.02M-24.0% |
| Net Income | -24.45M-8.2% |
| EPS | -2.45+34.7% |
| Shares Out | 10.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,913 |
| Open | 1.01 |
| Previous Close | 1.04 |
| Day's Range | 0.99 - 1.02 |
| 52-Week Range | 0.85 - 4.87 |
| Beta | 0.69 |
| Analysts | n/a |
| Price Target | 12.00(+1076.47%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About PLUR
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PLUR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PLUR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PLUR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PLUR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PLUR Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Revenues from external customers | $1.02M | 97.60% |
| Tax benefit | $25.00K | 2.40% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-K)
U.S. Patents
New PLUR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PLUR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PLUR
| ETF | Est. Holding Size |
|---|---|
| DFISDimensional - International Small Cap ETF | $0.5 |
Estimated from each fund’s disclosed top holdings × AUM
PLUR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PLUR’s recent data — informational, not investment advice